Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
株式のランク #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
株価
$9.60
最終同期: 2025-05-21
時価総額
$1.08B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 OptiNose, Inc. (OPTN)

カテゴリー

OptiNose, Inc.(OPTN)の利益
Mar 2025 時点の利益 TTM: $-29.89M
OptiNose, Inc. の最新の財務報告によると、同社の現在の利益は $-29.89M です。2023 年には $-35.48M の利益を上げ、これは 2022 年の利益 $-74.83M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
OptiNose, Inc. の利益の推移(2015 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-29.89M 38.76%
2024 $-21.54M -39.29%
2023 $-35.48M -52.58%
2022 $-74.83M -9.07%
2021 $-82.30M -17.53%
2020 $-99.79M -9.33%
2019 $-110.05M 3.18%
2018 $-106.66M 118.11%
2017 $-48.90M -316.26%
2016 $22.61M -179.87%
2015 $-28.31M 0.00%